TAILIN BIOTECH(SZ:300813) Zheng Quan Zhi Xing·2025-03-24 08:20Core Viewpoint - Zhejiang Tailin Biological Technology Co., Ltd. is implementing an employee stock ownership plan (ESOP) for 2025, which has been reviewed and approved by the legal counsel, Grandall Law Firm (Hangzhou) [2][15]. Group 1: Company Overview - Zhejiang Tailin Biological Technology Co., Ltd. is a legally established and effectively existing joint-stock company with a registered capital of 108.67663 million yuan [4]. - The company is listed on the Shenzhen Stock Exchange's Growth Enterprise Market, with its stock code being 300813, and it was officially listed on January 14, 2020 [5][7]. Group 2: Employee Stock Ownership Plan (ESOP) Details - The ESOP was approved during the fourth board meeting on March 11, 2025, and complies with relevant laws and regulations [8][15]. - The plan allows employees to voluntarily participate, ensuring no forced participation or financial assistance from the company [9][14]. - The stock acquired through the ESOP will have a lock-up period of 12, 24, and 36 months, with specific unlocking ratios of 40%, 30%, and 30% respectively [10]. Group 3: Legal Compliance and Procedures - The legal opinion confirms that the company has fulfilled necessary legal procedures for the ESOP, including obtaining approvals from the board and supervisory committee [12][15]. - The company must still hold a shareholders' meeting to approve the ESOP and disclose the legal opinion two trading days prior to the meeting [15][18]. - The ESOP does not create a concerted action relationship with controlling shareholders or management, ensuring compliance with relevant regulations [17]. Group 4: Information Disclosure - The company has disclosed the ESOP draft, management measures, and relevant resolutions through designated media [17][18]. - Ongoing information disclosure obligations will continue as the ESOP progresses, in accordance with regulatory requirements [18].